get a key
steadybase-$ company EOLS
account_id none on file
legal_name Evolus, Inc.
ticker EOLS
cik 1570562
domain evolus.com
entry_point_account_id none on file
name Evolus Inc.
exchange Nasdaq
sector Health Care
calls 5 filings 8 executives 8 family 0
why_nownone on file
calls
As it relates to how much profitability, I think we'll continue to assess that throughout the year, but we have great momentum going into 2024 and we continue to have disciplined operating expense management. So that enabled us to give us that revised guidance.

Mar 7, 2024 / receipt, needs a key / Sandra, CFO | earnings call 2024-03-07 | transcript a316d426-18d9-4a35-9c10-8bf53bbf9c05 | chars 28812-29073 | segment 29

And with our strong cash position and disciplined operating expense management, I am confident we are on track to achieving profitability and feel fortunate to have joined at such an exciting time on our growth journey.

Nov 8, 2022 / receipt, needs a key / Sandra Beaver, CFO | earnings call 2022-11-08 | transcript ee332f2d-6829-46a9-86a9-88a72da1e350 | chars 9909-10128 | segment 9

Demand for GVO remains strong this quarter, even with anticipated seasonality and the return of summer travel.

Nov 8, 2022 / receipt, needs a key / David Modizetti, CEO | earnings call 2022-11-08 | transcript ee332f2d-6829-46a9-86a9-88a72da1e350 | chars 3223-3333 | segment 3

The first is clearly seasonality took effect this year, and we're wrapping around on a prior year where consumers weren't traveling. And so I think you're seeing that effect resulting in some dampening in terms of the procedural growth rate versus prior year, and I think that was something that others have commented on as well.

Nov 8, 2022 / receipt, needs a key / Mark Goodman, analyst | earnings call 2022-11-08 | transcript ee332f2d-6829-46a9-86a9-88a72da1e350 | chars 18723-19052 | segment 18

This quarter is a bit different. We know consumers are traveling. You see airlines are at capacity in terms of their ability to support the influx of travel here in the third quarter, and I suspect that the traditional seasonality that we've seen prior to COVID is likely back in play, and that's what we're assuming.

Aug 2, 2022 / receipt, needs a key / David, CEO | earnings call 2022-08-02 | transcript 19ab3383-f797-43d1-99ec-81579fa9cb03 | chars 37391-37708 | segment 38

filings
Continued strength in international markets

ir_statement / Sep 15, 2026 / receipt

RAISED FULL-YEAR 2026 FINANCIAL OUTLOOK

ir_statement / Sep 15, 2026 / receipt

DOUBLE-DIGIT TOTAL REVENUE GROWTH WITH A LARGELY FLAT COST BASE DRIVES

ir_statement / Sep 15, 2026 / receipt

MINIMAL ADJUSTED OPERATING EXPENSE GROWTH 1% - 3%

ir_statement / Sep 15, 2026 / receipt

PROJECTED DOUBLE DIGIT REVENUE GROWTH

ir_statement / Sep 15, 2026 / receipt

Raises adjusted gross profit margin for the full-year 2026 to between 67.0% and 67.5%, from 65.5% to 67.0%, reflecting an evolving revenue mix while maintaining a disciplined approach to margin optimi

ir_statement / Sep 15, 2026 / receipt

Raises total net revenues for the full-year 2026 to between $330 million and $337 million, from $327 million to $337 million, which represents 11% to 13% growth over the prior year.

ir_statement / Sep 15, 2026 / receipt

The commercialization of the Estyme® collection in Europe

ir_statement / Sep 15, 2026 / receipt

executives
David Erickson CFO - receipt
David Moatazedi President and Chief Executive Officer - receipt
David Modazzetti CEO - receipt
David Modizetti CEO - receipt
David Modizzetti CEO - receipt
Lauren Silvernail Chief Financial Officer and EVP Corporate Development linkedin receipt
Sandra Beaver CFO - receipt
Tatjana Mitchell Chief Financial Officer - receipt
familynone on file
upcoming
2026-11-04 earnings call scheduled ir
changes
2025-09-08 Chief Financial Officer, appointed sec_8k
2025-08-05 Principal Financial Officer, appointed sec_8k
2022-08-30 Chief Financial Officer, appointed sec_8k
2018-06-01 Chief Financial Officer, appointed sec_8k
2018-05-10 President, appointed sec_8k
mcp_package_hint
steadybase-$